Hepion Pharmaceuticals (HEPA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, at 9:00 a.m. in New York, NY.

• Proxy materials and 2025 Annual Report are available online, with options for paper or email copies upon request.

• Voting can be conducted online, by mail, or in person, with specific instructions provided for each method.

Voting matters and shareholder proposals

• Election of five directors: Vincent LoPriore, Gary Stetz, Chase LoPriore, Michael Purcell, and Sireesh Appajosyula.

• Ratification of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Approval of amendment to the 2023 Omnibus Equity Incentive Plan, increasing shares issuable to 8,000,000 from 200,000.

• Board recommends voting "FOR" all nominees and proposals.

Board of directors and corporate governance

• Board slate includes five nominees, with Vincent LoPriore serving as Executive Chairman.

• Board oversight includes recommendations on all voting matters.